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ABSTRACT
Breast cancer is the leading cause of cancer deaths among females. The aims of this study were
to find the most common histological types of the breast cancer in the West Bank/Palestine, their
stages, receptor status and the strategies of treatment. This was a retrospective study that was conducted in two major outpatient clinics for oncology. The data collection form was completed by
reviewing patients’ medical records. SPSS program was used for data analysis. The study included
400 women; their average of age was 52.16 ± 11.56 years. Ductal carcinoma was the most common
317 (79.3%), then lobular in 60 (15.0%). The highest number of patients 106 (26.5%) were diagnosed in stage three, 100 (25.0%) in stage two, 95 (23.8%) in stage four, and 81 (20.3%) stage one.
About potential predictive biomarkers, it was found that most patients 353 (88.3%) did not test
BRCA1/BRCA2, among the rest who had the test 21 (5.3%) were positive. Regarding Estrogen
Receptor (ER), 249 out of 386 (64.5%) for whom the data was available in files had positive test,
whereas Progesterone Receptor (PR) test was positive in 225 (58.34%) women out of 385. For
HER2 receptor, most patients had negative results 306 (80.3%). The most common type of breast
cancer among Palestinian women was invasive ductal carcinoma. Around half of the patients were
diagnosed in stage three and four, so better awareness regarding this disease is recommended. A
high percentage of patients had positive ER and PR, this makes hormone therapy an important part
of treatment.
Keywords: Breast Cancer, Stages, Receptors, Palestine.
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INTRODUCTION
Cancer is one of the major causes of
morbidity and mortality in Palestine, with
lung cancer as the most common type in
males and breast cancer in females, in 2015,
breast cancer accounted for 33.7% of cancer
types reported among females and the incidence rate was 33.1 per 100000 [1]. Breast
cancer is the most common cancer in women
around the world and is the leading cause of
cancer deaths among females [2]. It is very
important to discover breast cancer as early
as possible bacause this will increase the cure
rate, so screening is recommended especially
after the age of 40 years. Mamography,
clinical and self- breast examination can
identify tumers at early stages and small size
which reduces morbidity and mortality [3].

Breast cancer differs from other types of
cancer as it is affected by female sex
hormones for development and growth [4].
Estrogen and progesterone help regulate
growth and differentiation of normal breast
tissue, and they are considered important in
the development and progression of breast
cancer [5]. Clinically, estrogen receptors
(ER) and progesterone receptors (PR) levels
in breast cancer tissue have been used as
prognostic indicators to predict a patient's
course of disease and response to adjuvant
hormonal therapy. In general, women whose
tumors are positive for both ER and PR
survive longer and respond better to
endocrine therapy [6].
In addition, about 1 of 5 breast cancers
have an increased growth-promoting protein
called human epidermal growth factor
receptor 2 (HER2/neu). The HER2/neu gene
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induces the cells to make this protein.
Tumors with high levels of HER2/neu are
referred to as HER2- positive. . Such cancers
tend to grow and spread in an aggressive
way. All newly diagnosed invasive breast
cancers should be tested for HER2/neu and
the positive ones may benefit from treatment
with drugs that target the HER2/neu protein
[7].
A small proportion of women has a
particularly strong family history of breast
cancer and are at very high risk. Mutations in
the breast cancer susceptibility genes BRCA1
and BRCA2 account for the majority of
families with four or more affected members
and 2-5% of all breast cancers [8]. Families
with this mutation require more tests at
earlier ages due to high risk of breast and
overian cancers. Breast cancer is related to
many environmental, reproductive, and lifestyle factors, some of which are potentially
modifiable [9]. So, it is important to consider
these risk factors to give more attention to
women with some of them.
There are various treatment plans for
cancer patient depending on the type and the
stage at diagnosis. Surgical treatment for
breast cancer includes breast-conserving surgery or mastectomy, in addition to chemotherapy; radiation therapy and hormonal therapy
[10, 11].
Cancer in the West Bank is a public
health problem. The most common cause of
death out of all cancer types was breast cancer among females, so by knowing the risk
factors associated with breast cancer, the
most common histological types, the types of
receptors and the stages among Palestinian
women, suitable planning and recommendations for screening and treatment can be given. To the best of our knowledge, this is the
first study in Palestine with these objectives.
The aims of this study are to find the
most common histological types of breast
cancer in the west bank, their stages, receptor
status and the strategies of treatment.

tient clinics for oncology patients in Palestine; (Al-Watani Governmental Hospital /
Nablus and Al-Hussein Governmental Hospital/ Beit Jala).
Medical records of breast cancer patients
who visited the included clinics were reviewed for types of breast cancer, stages, receptor types and treatment.
Inclusion criteria included breast cancer
women who were diagnosed with the disease
and were treated for this at the time of the
study. Men with breast cancer were excluded.
Sample size
The number of current breast cancer patients in Palestine is not available. However,
the new reported cases in the west bank in
2015 were 427 [1] and in 2014, they were
387, the unofficial estimate from the working
oncologists was around 2000 patients. Using
Roasoft sample size calculator, the minimum
sample size for this study was calculated to
be 323 patients. So, the target was 400 patients.
Data collection
Patient’s medical records were reviewed. Patient’s age, medical conditions,
cancer type and stage, laboratory and other
diagnostic tests, in addition to all breast cancer prescribed medications and other treatment modalities were documented from the
patient’s files.
The study protocol was authorized by
An-Najah National University Institutional
Review Boards (IRB) and the Ministry of
Health before initiation of this study.
Statistical analysis
Statistical analysis was performed using
Statistical Package for Social Sciences (SPSS
version 21). Mean ± standard deviation (SD)
was computed for continuous data. Frequencies and percentages were calculated for categorical variables. Chi-square test was used
to compare categorical variables, a p value
<0.05 was considered statistically significant.

METHODS
Study design and selection criteria
The study was a retrospective cohort
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RESULTS
Socio-demographic characteristics of the
patients
During the study period, a total of 400
medical records were reviewed. The average
age (± SD) of patients was 52.16 ± 11.56
years, and the maximum age was 82 years
while the minimum age was 25 years. The
majority 295 (73.8%) were married, 166

(41.5%) of them were pregnant before. Seventy (17.5%) patients were smokers and 61
(15.3%) used contraceptive before. Regarding breast feeding 118 (29.5%) had never
been breast feeding before, 275 (68.8%) of
them were diagnosed before one to five
years, whereas 20 (5.0%) suffered from recurrence of cancer. Table 1 shows sociodemographic characteristics of the patients.

Table (1): Sociodemographic characteristics of the patients (N=400).
Characteristic
Marital status
Married
Single
No Information
Being pregnant before
Yes
No
No Information
Breast feeding before
Yes
No
No Information
Family history of cancer
Yes
No
No Information
Time since diagnosis
Less than one year
1-5 years
5-10 years
More than ten years
Recurrence of the cancer
Yes
No
No Information

Frequency

Percentage (%)

295
53
52

73.7
13.3
13.0

166
69
165

41.5
17.3
41.2

75
118
207

18.8
29.5
51.8

120
208
72

30.0
52.0
18.0

117
275
7
1

29.3
68.8
1.8
0.3

20
105
275

5.0
26.3
68.7

Other comorbid diseases

Cancer types and stages

The 400 patients had 0-4 diseases (excluding breast cancer). About 148 (37.0%) of
them had no co morbid diseases. The most
common diseases were hypertension 82
(32.5%) and diabetes mellitus (DM) 72
(28.0%) (Type 1 and 2). Other diseases that
were found included hyperlipidemia 13
(5.0%), thyroid disease 10 (3.9%), uterine
fibrosis 10 (3.9%), ovarian cancer 12 (4.7%),
liver disease 13 (6.3%), lung disease 10
(3.9%), kidney disease 11(4.3%), and coronary heart disease which was the least common 3 (1.0%).

Four types of breast cancer were identified in the patients; ductal carcinoma was the
most common 317 (79.3%), then lobular 60
(15.0%), invasive 18 (4.5%) and inflammatory 5 (1.3%) which was the least common.
The average duration of cancer was
24.84±31.84 months.
Regarding laterality, half patients 200
(50.0%) had left breast cancer, 186 (46.5%)
had right breast cancer and the rest had cancer in both sides.
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There are five stages of breast cancer,
from stage zero to stage four, the highest
number of patients 106 (26.5%) were in stage
three, and 100 (25.0%) in stage two, 95
(23.8%) in stage four, 81 (20.3%) in stage
one and 17 (4.3%) in stage zero (Figure 1).

Figure (1): Stages of breast cancer at the time of diagnosis.
0.385). Progesterone Receptor (PR) test was
Genetic and receptor status tests
positive in 225 (58.34%) women out of 385,
About potential predictive biomarkers, it
the test was positive in women <40 years but
was found that most patients 353 (88.3%) did
the difference was not significant also
not test BRCA1/BRCA2, among the rest who
(64.2% vs 57.5%; p value = 0.364). The files
had the test 21 (5.2%) were positive and 26
that included data about HER2 receptors
(6.5%) were negative. Regarding Estrogen
were 381 files; most patients had negative
Receptor (ER), 249 out of 386 (64.5%) for
results 306 (80.3%) while 75 (19.7%) of 381
whom the data was available in files had poshad positive results. Table 2 shows tests
itive test, ER positive test was more among
which were available in patients’ files.
women <40 years but it did not reach a significant level (69.8% vs 63.7%; P value =
Table (2): Results of genetic and receptor status tests related to breast cancer.
Test
BRCA1/BRCA2
Positive
Negative
No information
Estrogen Receptors
Positive
Negative
Progesterone Receptor
Positive
Negative
HER2 Receptor
Positive
Negative

Number of patients for whom
the data was available
400

Frequency

Percentage (%)

21
26
353

5.3
6.5
88.3

249
137

64.5
35.5

225
160

58.4
41.6

75
306

19.7
80.3

386

385

381
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Treatments and medications
There were three major treatment types
(chemotherapy, radiotherapy and hormonal
therapy) for patients, 366 (91.5%) patients
received chemotherapy, whereas 185 (46.3%)
underwent radiotherapy. Moreover, treatment
intent for most patients 305 (76.2%) was curative while for the others 95 (23.8%) who
were in stage four, it was palliative.
A total of 33 different medications were
used by the patients. The patients were prescribed 1 to 10 medications with a median of
5. Cyclophosphamide was the most common
medication, being used by 277 (69.3%) patients. Followed by adriamycin, paclitaxel
and tamoxifen which were used by 202
(50.5%), 140 (35.0%) and 128 (32.0%) patients respectively.
DISCUSSION
In this study, the highest percentages of
patients were diagnosed in stage two and
three (25% and 26% respectively). Compared
to another study in Turkey, stage one and two
were the highest 27.0% and 44.0% respectively [12] . Around half of the patients in
this study were diagnosed in stage three or
four; this indicates the need for more selfexamination and mammography as the discovery of the disease in earlier stages increases the possibility of cure.
Regarding genetic and receptor tests, this
study shows that ER was positive in 64.5%
and PR was positive in 58.4% cases, it is approximately similar to another study in Japan
where ER was positive in 75.8% and PR in
62.1% [13]. About HER2 ,we found that
19.7% had positive results, but in a study
from Turkey that was 8.5% [12] .
The most common histological type was
invasive ductal carcinoma in 79.3%, in a
study in Morocco, it was 80.7% of cases [14]
. Invasive lobular carcinoma was the second
most common type in 15% patients. It is the
second most common type of breast cancer
after invasive ductal carcinoma in other parts
of world accounting for 5%–15% of all the
breast cancer cases [15]. The results confirm
that inflammatory breast cancer is the least
common type of cancer among women [16].

Regarding laterality, it was found that
half cancer cases were in the left side 50%,
then the right 46.6% and bilateral was the in
2.5% cases. This is the same in Shiraz study
which showed that half of the sample had the
cancer in the left side [17]. Also in Casablanca study which showed that bilateral breast
cancer represents a small percentage of all
breast cancers (2.4%) [18].
In our study, the most common chemotherapy was cyclophosphamide 69.25%,
adriamycin was the next common 50.5% and
then paclitaxel 35%. About hormonal therapy, we found that tamoxifen had the highest
percentage with 32% and letrazol 13%.
These medications are among the most commonly used medications for breast cancer in
international protocols, so this is expected.
The limitations of this study include the
sampling method which was convenient, that
limits our ability to make wider generalizations from the results. The second limitation
was that the study was performed in two governmental hospitals only. Although these
hospitals have the two major oncology centers in the West Bank, they might not be representative to the whole West Bank. Also,
not all the required data was available in
some files. However, these results can give
baseline data that can be useful in planning
policies.
CONCLUSIONS
The most common type of breast cancer
among Palestinian women is invasive ductal
carcinoma. Around half of the patients were
diagnosed in stage three and four, so better
awareness regarding this disease is recommended to diagnose it earlier. A high percentage of patients have estrogen and progesterone positive receptors, this makes hormone
therapy an important part of treatment. The
results of this study can help clinician make
treatment choice and policy makers implement programs against this disease.
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